Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-25-053771
Filing Date
2025-04-14
Accepted
2025-04-14 17:05:34
Documents
19
Period of Report
2025-06-10

Document Format Files

Seq Description Document Type Size
1 PRE 14A eldn-20250414.htm   iXBRL PRE 14A 1038552
2 GRAPHIC img118025860_0.jpg GRAPHIC 191772
3 GRAPHIC img118025860_1.jpg GRAPHIC 959267
4 GRAPHIC img118025860_2.jpg GRAPHIC 935638
5 GRAPHIC img118025860_3.jpg GRAPHIC 1388381
6 GRAPHIC img118025860_4.jpg GRAPHIC 147454
  Complete submission text file 0000950170-25-053771.txt   10516129

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eldn-20250414.xsd EX-101.SCH 12025
21 EXTRACTED XBRL INSTANCE DOCUMENT eldn-20250414_htm.xml XML 365619
Mailing Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612
Business Address 19800 MACARTHUR BLVD. SUITE 250 IRVINE CA 92612 949-238-8090
Eledon Pharmaceuticals, Inc. (Filer) CIK: 0001404281 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36620 | Film No.: 25836669
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)